MOREPENLAB
Morepen Laboratories Limited
Each stock's 10,000-path forecast, rendered as light.
Morepen Laboratories Limited (MOREPENLAB) Stock Analysis & Case Study
Is MOREPENLAB a good buy? The data-driven verdict.
Morepen Laboratories Limited (MOREPENLAB) trades at ₹80,on the numbers it tread carefully, a Downstox Snapshot Score of 34/100.
On the numbers, Morepen Laboratories Limited (MOREPENLAB) tread carefully, a Downstox Snapshot Score of 34/100, weighing premium at 37.4× earnings, ROE of 6.2%, a 49% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MOREPENLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MOREPENLAB ranks against the 2,373 companies in our screener
- MOREPENLAB's market cap of 4,397 Cr ranks in the 64th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's book value of ₹23 ranks in the 20th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's promoter holding of 35.7% ranks in the 12th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's 3-year profit (PAT) growth of 24.0% ranks in the 62nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's 3-year revenue growth of 8.0% ranks in the 44th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's debt-to-equity ratio of 0.17x is lower than 66% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is MOREPENLAB overvalued? MOREPENLAB P/E vs peers
MOREPENLAB trades at 37.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
MOREPENLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of MOREPENLAB history (12%/yr drift, 52%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MOREPENLAB 2027 | ₹40 | ₹79 | ₹156 | -1% |
| MOREPENLAB 2028 | ₹30 | ₹78 | ₹204 | -3% |
| MOREPENLAB 2029 | ₹24 | ₹77 | ₹245 | -4% |
| MOREPENLAB 2030 | ₹20 | ₹76 | ₹287 | -6% |
| MOREPENLAB 2031 | ₹17 | ₹75 | ₹332 | -7% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MOREPENLAB goes up, or doubles?
The bull case for MOREPENLAB
- Morepen Laboratories Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹245.
The bear case & risks
- MOREPENLAB's P/E of 37.4x is lower than 36% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- MOREPENLAB's return on equity of 6.2% ranks in the 34th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (52%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹24.
MOREPENLAB volatility & expected range, how bumpy is the ride?
Over the last 9.8 years MOREPENLAB compounded at 12%/year with annualized volatility of 52%. That volatility implies a 1-year 80% range of ₹40-₹156, the honest backbone behind any single price target.
MOREPENLAB price forecast, the full 60-month probability fan
MOREPENLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MOREPENLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the MOREPENLAB price target & forecast page.
MOREPENLAB Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MOREPENLAB scores 6/8, mixed financial health.
MOREPENLAB MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy MOREPENLAB with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 40.16% | 2.5× |
| Groww | 50.00% | 2.0× |
| Dhan | 64.00% | 1.6× |
| Kotak Neo | 50.00% | 2.0× |
| Paytm Money | 46.22% | 2.2× |
| PocketfulCHEAPEST | 37.80% | 2.6× |
| Anand Rathi | 40.16% | 2.5× |
| Bajaj Broking | 64.00% | 1.6× |
| Share India | 37.84% | 2.6× |
Compare every broker on the MOREPENLAB MTF page.
About Morepen Laboratories Limited: sector, index & market-cap context
Morepen Laboratories Limited (MOREPENLAB) is a small-cap NSE-listed company, with a market capitalisation of ₹4,397 Cr. See more stocks on our screener.
How the MOREPENLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Morepen Laboratories Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MOREPENLAB analysis, FAQs
Is Morepen Laboratories Limited (MOREPENLAB) a good buy?
On the numbers, Morepen Laboratories Limited (MOREPENLAB) tread carefully, a Downstox Snapshot Score of 34/100, weighing premium at 37.4× earnings, ROE of 6.2%, a 49% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MOREPENLAB overvalued or undervalued?
MOREPENLAB trades at 37.4× earnings, premium versus the ~22× long-run Nifty average.
What is the MOREPENLAB share price target for 2031?
MOREPENLAB's probability-weighted 2031 median target is ₹75, with an 80% range of ₹17-₹332 (10,000-path Monte-Carlo).
What is the probability MOREPENLAB doubles in 5 years?
The modelled probability of MOREPENLAB reaching ₹161 (2×) within 5 years is 25%.
What is the bull case for MOREPENLAB?
Morepen Laboratories Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in MOREPENLAB?
MOREPENLAB's P/E of 37.4x is lower than 36% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. MOREPENLAB's return on equity of 6.2% ranks in the 34th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (52%/yr) means a wide, bumpy range of outcomes, size positions accordingly.